Nitric oxide has been implicated in N-methyl D-aspartate (NMDA)-mediated damage in vitro; how ever, its role in excitotoxic damage in vivo is not clear. In the present study we evaluated the histopathological and hemodynamic consequences of intrastriatal injections of various doses of NMDA and determined the effects of nitric oxide synthase inhibition on these changes. NMDA was injected into the striatum at doses of 50, 150, and 300 nmol with or without NW-nitro-L-arginine methyl ester (L NAME; 100 I-lg, locally). Three days following injections histopathological assessment was performed by morpho metric analysis of the lesion area in multiple sections taken from the anterior to the posterior borders of the lesion. In animals injected with 150 and 300 nmol of NMDA (±L-NAME), local CBF (ICBF) was determined 30 min following injections using 14C-iodoantipyrine au toradiography. All NMDA-treated animals showed a well-demarcated lesion extending beyond the injection site. The volume of the lesion correlated significantly with the NMDA dose injected. The effects of L-NAME on lesion size were dependent on the dose of the NMDA. The lesion induced by 50 nmol of NMDA was not affected by L-NAME. With a dose of 150 nmol of NMDA, Nitric oxide (NO) is a small diffusible molecule that recently has been identified as a neuronal mes senger involved in glutamate neurotransmission. Glutamate, acting on N-methyl-D-aspartate (NMDA) receptors in cultures of cerebellar granule cells, has been shown to release a factor resembling NO with the ability to cause vasodilation and raise
L-NAME induced a 43% increase in lesion volume. In contrast, a 38% decrease in lesion size was observed in animals treated with 300 nmol of NMDA combined with L-NAME. At a dose of 150 nmol, NMDA induced a sig nificant elevation in lCBF, which was restricted to re gions close to the injection site including the center areas of the anterior and middle striatum. The increase in lCBF observed with 150 nmol of NMDA was significantly at tenuated In the NMDA + L-NAME-treated group. The lCBF changes induced by 300 nmol of NMDA were not significantly different from those in the I50-nmol group; however, the extent of the regions involved was larger. The increases in lCBF were observed in all striatal re gions including the central and peripheral areas. L-NAME did not have a significant effect on the lCBF changes induced by NMDA at a dose of 300 nmol. These data suggest that in vivo the involvement of nitric oxide in NMDA toxicity depends on the NMDA dose and on the participation of hemodynamic mechanisms secondary to NMDA exposure. Ke y Words: Excitotoxicity Glutamate-Nitric oxide-N-Methyl-D-aspartate Striatum.
cyclic GMP (cGMP) levels (Garthwaite et aI., 1988) . Subsequent studies demonstrated that glutamate agonists stimulate NO synthase (NOS) activity (Kiedrowski et aI., 1992) and increase cGMP by NO-mediated mechanisms (Bredt and Snyder, 1989; Wood et ai. , 1990) . Similar findings were found in hippocampal slices (East and Garthwaite, 1991) , primary cortical cultures (Dawson et ai., 1991) , and striatal slices (Kollegger et ai., 1993) . Thus, NMDA receptor activation by glutamate is a major trigger for NO formation in several areas of the brain. The demonstration that selective inhibi tors of NOS prevent glutamate-mediated cell death (Dawson et ai., 1991 (Dawson et ai., , 1993 Izumi et ai., 1992; Kollegger et al., 1993) provided evidence that NO is involved in the processes leading to glutamate neu rotoxicity in vitro. However, other in vitro studies were not able to demonstrate such protection with NOS inhibitors (Demerle-Pallardy et ai., 1991; Pau wels and Leysen, 1992; Hewett et ai. , 1993) . There is no explanation for the inconsistent results with these drugs, but the severity of the excitotoxic ex posure may be important in determining the effi cacy of these agents.
While the relationship between NO and gluta mate toxicity has been extensively investigated in vitro, in vivo studies are scarce. Systemic adminis tration of NOS inhibitor (NW-nitro-L-arginine meth yl ester; L-NAME) was shown to attenuate the de gree of damage induced by local injection of NMDA into the striatum (Buisson et ai. , 1993) or dorsal hippocampus (Moncada et ai., 1992) . While these results provide further support for the modulatory role of NO in glutamate neurotoxicity, several is sues are left unanswered. In pial window prepara tions, NMDA has been shown to induce vasodila tion that is dependent on neuronal activation and NO synthesis (Faraci and Breese, 1993) . Because the hemodynamic response to NMDA may play a role in the excitotoxic process, it is important to determine the magnitude of these changes and eval uate whether the effects of NOS inhibition on these hemodynamic alterations confound the histopath ological outcome following NMDA exposure. Fur thermore, because the severity of the excitotoxic exposure may be an important factor, it would be essential to determine the effects of NOS inhibition on the magnitude of damage following various doses of NMDA. The present study was designed to examine the histopathological and hemodynamic consequences of intrastriatal injections of various doses of NMDA and to determine the effects of NOS inhibition on these changes. The results en able us to establish a relationship between NO and the hemodynamic and histopathological conse quences of NMDA exposure in vivo.
MATERIALS AND METHODS

Focal injections of NMDA
Male Wi star rats (300-350 g) were anesthetized with halothane and femoral vessels were cannulated for phys iological monitoring. The rats were then intubated and mechanically ventilated to maintain P ac02 and Pa02 within the normal ranges. The animals were then placed in a stereotaxic frame and a burr hole was placed over the striatum (stereotactic coordinates: 0.7 mm anterior and 3 mm lateral to the bregma). NMDA (50, 150, or 300 nmol in 2 f.11, dissolved in 0. 1 M sodium phosphate-buffered saline. pH 7) was infused into the striatum through a nee dle placed 6.5 mm ventral to the dura. All focal injections were carried out over 6 min, and the needle was left in place for an additional 15 min. The injection site was similar in all experimental groups. Animals received ei ther NMDA (50, 150, or 300 nmol), L-NAME (100 f.1g injected focally). or a combination of NMDA with L-NAME. Five or six animals were included in each treatment group, and the volume of injection (2 f.11) was the same for all experimental groups. We have chosen the focal injection of L-NAME instead of parenteral admin istration to avoid general hemodynamic effects and to achieve better inhibition of NOS activity. Our data show a 90% reduction in enzyme activity (Bredt and Snyder, 1990) around the injection site 30 min following local ad ministration of 100 f.1g of L-NAME.
Histopathological assessment
Histopathological assessment of the size of the lesion induced by NMDA was performed 3 days following NMDA injections. Animals were transcardially perfused with a mixture of 40% formaldehyde, glacial acetic acid, and absolute methanol (1: 1 :8, by volume). Brains were then embedded in paraffin, and lO-f.1m-thick sections were obtained in serial fashion through the whole stria tum and stained with hematoxylin and eosin. At low power (I x), the damaged area was identified and traced onto paper using a camera lucida attachment. Each draw ing was then traced onto a digitizing tablet (Summagraph ics) interfaced to the MicroVAX system, which computed the size of the damaged areas at each coronal level. The total volume of lesion was derived by means of numerical integration of the sequential damaged areas.
Cerebral blood flow (CBF) studies
In a separate set of animals injected with 150 or 300 nmol of NMDA (with or without L-NAME), or with L-NAME or vehicle, local CBF (ICBF) studies were per formed by the 14C-iodoantipyrine technique (Sakurada et al.. 1978) . Six animals were included in each treatment group. Blood flow measurements were conducted 30 min following injections because at that time maximal reduc tion in NOS activity was demonstrated (90%). Thirty min utes following drug injection, 65 f.1Ci/kg of 14C_ iodoantipyrine (New England Nuclear) dissolved in 1 ml of isotonic saline was infused intravenously at a constant rate over 45 s via a Harvard infusion pump. Arterial blood was sampled at 2-s intervals from the tip of a freely flow ing femoral arterial catheter and collected in precalibrated 20-f.11 heparinized capillary pipettes. The study was ter minated by decapitation with an automated guillotine. Brains were quickly removed from the skull and frozen by suspension over, and gradual immersion into, liquid nitrogen. For preparation of autoradiograms, the brains were warmed in a crysostat to -20°C and coronal sec tions, 20 f.1m in thickness, were prepared in quadruplicate at 500-f.1m intervals. Through the striatum, subserial sec tions were prepared at 80-f.1m intervals. The dried sec tions together with 14C-methacrylate standards (Amer sham) were then exposed to Hyperfilm Bmax autoradiog raphy film for 10 days. Autoradiographic images were digitized on a rotating-drum densitometer (Optronics C-4 100) interfaced to a MicroV AX minicomputer system. Coronal autoradiographic images for each rat were aligned by a novel disparity-analysis method developed in our laboratory (Zhao et al., 1993) , permitting three dimensional display and resectioning of the image stack in the horizontal plane (see Fig. 7 ). Region-of-interest anal ysis was performed in the anterior, middle, and posterior striatum. At every striatal level, separate analysis was performed for the epicenter and the periphery of the NMDA injection site.
Statistical analysis
Data were analyzed by means of SYST AT and SAS general linear model procedures. Two-way analysis of variance (ANOY A) was used for the comparison of lesion volume among the NMDA and NMDA + L-NAME treatment groups. The Bonferroni procedure was used to correct for multiple comparisons. For every experimental (i.e., NMDA dose), a repeated-measures ANOYA was employed to test sequential lesion areas for overall be tween-subject effects with respect to treatment (NMDA ± L-NAME) and to assess within-subjects effects (with respect to lesion area and area * treatment interactions). Repeated-measures ANOY A was also used for lCBF analysis, in which the region and hemispheric side were the repeated measures. Univariate analysis was used for evaluating significant effects of treatment within each re gion. In addition, in each treatment group side-to-side differences (noninjected and injected hemispheres) in ICBF were analyzed by paired t tests.
RESULTS
Histopathological data
Light microscopic analysis of the L-NAME infused animals demonstrated no morphological damage to the neuronal parenchyma extending be yond the injection site (data not shown). In con trast, all NMDA-treated animals displayed a well demarcated lesion extending beyond the injection site ( Fig. IA) . In the central striatum surrounding the injection site, the parenchyma appeared ne crotic ( Fig. I B) . At more distal regions a transi tional zone between necrotic and normal-appearing parenchyma was observed (Fig. Ie) . This region displayed selective neuronal necrosis within a rela tively intact parenchyma. Figure 2 demonstrates the lesion volumes in the NMDA-treated animals. Two factor ANOYA (NMDA, L-NAME) revealed a highly significant overall effect of NMDA treat ment on lesion volume (F2.31 = 20, p < 0.001), with no overall significant effects for L-NAME (F1,31 = 0.5, p = 0.508), However, a significant NMDA * L-NAME interaction (Fl,31 = 6, p = 0.006) was found, ifJdicating a ' significant effect of L-NAME Post hoc tests revealed significant differences (p < 0. 01) between lesion volumes induced by the differ ent doses of NMDA (50 vs. 150, 50 vs. 300, and 150 vs. 300 nmol). These results indicate that there is a relationship between the NMDA dose and the vol ume of the lesion-a profound increase in the extent of the lesion is observed with increasing doses of NMDA. Interestingly, the · effects of L-NAME on lesion size were dependent on the dose of the NMDA. The lesion induced by 50 nmol of NMDA was not affected by L-NAME. With 150 nmol of NMDA, L-NAME induced a 43% increase in lesion o NMOA (50 nmols) 0.593), suggesting that the lesion area induced by 50 nmol of NMDA was not affected by L-NAME. However, the lesion areas induced by 150 and 300 nmol of NMDA were significantly affected by L-NAME (between-subjects comparison: Fl.l1 = 5.4, p = 0.04, and Fl.lo = 5.6, p = 0.039, respec tively). While the extent of the lesion induced by 150 nmol of NMDA increased with L-NAME, the magnitude of damage induced by 300 nmol was re duced. These effects of L-NAME are evident in Figs. 4 and 5. Figure 6 demonstrates the effect of the NMDA ± L-NAME treatment on ICBF in the vicinity of the injected site on the contralateral (Fig. 6A ) and ipsi lateral (Fig. 6B) hemispheres. Both 150 and 300 nmol of NMDA induced an increase in ICBF com pared to the vehicle-treated animals. The effect of NMDA treatment was confined to the injected hemisphere, with no detectable changes on the con tralateral side. Two-way ANOV A in which the re gions and the hemispheric side were repeated mea sures revealed an overall significance for treatment (between-subjects comparison: F5•26 = 2.93, p = 0.031). Tests for within-subjects effects revealed overall significance for region (F 6 . 156 = 21.12, p = 0.0001) but not for hemispheric side (F1.26 = 0.17, p = 0.68).
CBF data
Overall significance for treatment was detected in the anterior (central, F5•26 = 9.51, p = 0.0001; pe ripheral, F5•26 = 6.28, p = 0.0006), middle (central, FS•26 = 9.22, p = 0.0001; peripheral, FS•26 = 8.04, J Cereb Blood Flow Me/ab, Vol. 15, No. 6, 1995 p = 0.0001), and posterior (central, FS.26 = 4.41, p = 0.0049; peripheral, FS,26 = 4.31, p = 0.0055) striatal regions. No significant effects were detected in the frontal cortex (data not shown). The specific effects of treatment were analyzed by post hoc tests. ICBF in the L-NAME-treated group was not different from that in vehicle-treated animals. At a dose of 150 nmol, NMDA induced a significant el evation in ICBF that was restricted to regions close to the injection site including the central areas of the anterior and middle striatum. The increases ob served with 150 nmol of NMDA were significantly attenuated in the NMDA + L-NAME-treated group. The ICBF changes induced by 300 nmol of NMDA were not significantly different from those in the 150-nmol group; however, the extent of the regions involved was larger. The increases in ICBF were observed in all striatal regions including the central and peripheral areas. L-NAME did not have a significant effect on the ICBF changes induced by NMDA at a dose of 300 nmol. Figure 7 displays ICBF autoradiograms of representative brains of each experimental group in coronal and horizontal views through the striatum. Figure 8 illustrates the ratios between the ICBF on the treated and those on the nontreated side, representing the differences in ICBF between the two hemispheres. Side-to-side differences were an alyzed by paired t tests. Injection of vehicle signif icantly reduced ICBF, by �40%. Maximal reduc tions were observed in the injection site (the center of the middle striatum). Similar reductions were ob served in the L-NAME-treated group, indicating that NOS inhibition did not further reduce lCBF. Significant differences between the treated and the nontreated hemispheres were demonstrated in the NMDA-injected animals. These differences repre sent a significant elevation in ICBF induced by both doses of NMDA. In animals in which coinjection of NMDA and L-NAME was performed, no side-to side differences were observed.
DISCUSSION
The salient findings of this study are (a) the dem onstration that the magnitude of damage induced by NMDA in vivo is dose dependent; (b) in contrast to the results described in vitro, the effects of NOS inhibition on NMDA-induced damage in vivo are dependent on the degree of NMDA exposure; (c) intracerebral injections of NMDA induce a signifi cant increase in ICBF whose extent is dose depen- dent; and (d) in parallel with the histopathological data, the dependency of lCBF changes induced by NMDA on NO production was also found to be contingent on the degree of NMDA exposure. In vitro, the magnitude of damage induced by NMDA is proportional to the concentration of NMDA and to the duration of exposure (Dawson et aI., 1993) . Therefore, it is not surprising that the magnitude of damage induced by local injections of NMDA in vivo is also dose dependent. Increasing the concentration of NMDA in the injection volume subjects the cells in the proximity of the injection site to higher levels of NMDA. In addition, it leads to enlargement of the diffusion area of the drug, thus expanding the volume of the region exposed to toxic levels of NMDA.
The mechanisms involved in NMDA toxicity in volve influx of calcium through the NMDA-gated cation channel, leading to increased intracellular calcium, which triggers a cascade of events that ul timately lead to cell death (Choi et aI., 1987) . Among the intracellular events that are stimulated by calcium are the activation of NOS and the gen eration of NO (Forstermann et aI., 1991) . The in volvement of this process in NMDA-mediated dam age is evident from recent in vitro studies describing a beneficial effect of NOS inhibitors in cell cultures exposed to NMDA (Dawson et aI., 1991 (Dawson et aI., , 1993 Izumi et aI., 1992; Kollegger et aI., 1993) . However, our results show that the relationship between NO and NMDA toxicity in vivo is more complex and is dependent on the degree of exposure to NMDA. 150 nmol NMDA + L-NAME; and E and F, 300 nmol NMDA; G and H, 300 nmol NMDA + L-NAME) in coronal and horizontal sections through a computer-aligned three-dimensional image data set. NOS inhibition led to a significant attenuation of lesion volume induced by 300 nmol of NMDA. However, with lower doses of NMDA, either no change (50 nmol) or an increase (150 nmol) in lesion volume was observed with NOS inhibition. The diverse effects of NOS inhibition on NMDA toxicity in vivo are likely a reflection of the multi faceted roles of NO in vivo. Among these, the he modynamic influences of NO may play an impor tant role in modulating NMDA toxicity. The partic ipatory role of NO in maintaining cerebral perfusion is evident from studies demonstrating constriction of pial arteries by L-NAME when superperfused over the brain surface (Rosenblum et al., 1990) or when injected into the carotid artery (Gotoh et aI., 1991) . The reported reduction in regional CBF within minutes of intravenous administration of L-NAME provides further support for NO as an important mediator of cerebral vascular control (Tanaka et aI. , 1991; Kozniewska et aI. , 1992) . The involvement of NO in coupling neuronal actIvity with changes in ICBF has also been proposed (Dirnagl et aI. , 1993) . One example of such coupling is the vascular response to NMDA. Although cere bral microvessels may not contain NMDA recep tors (Beart et aI. , 1988) , NMDA has been found to induce vasodilation in pial window preparations (Faraci and Breese, 1993) . The vasodilatory re sponse to NMDA was found to be dependent on neuronal activation and modulated by NO (Faraci and Breese, 1993) . Our results provide further sup port for the vascular effect of NMDA and for the modulatory role of NO. Direct injections of NMDA into the striatum induced a profound increase in ICBF, which, depending on the NMDA dose used, extended beyond the injection site and was attenu ated by NOS inhibition. The observed increase in ICBF is most likely mediated by a surge in neuronal activity in response to NMDA receptor activation. Thus, it represents a mechanism to provide an ad equate blood supply to support the increased met abolic demand of the excited neurons. NO may therefore have a double-edged role in NMDA tox icity in vivo. It plays a detrimental role by partici pating in the intracellular cascade of events leading to cell death following NMDA receptor activation (Dawson et aI. , 1993) . On the other hand, NO is also essential in providing an adequate blood supply to match the increased metabolic demands. The final outcome depends on the balance between these two processes. One may speculate, therefore, that the lesion volume induced by 150 nmol of NMDA was significantly augmented by NOS inhibition because of suppression of the blood flow response. The ad ditional damage seen with increasing doses of NMDA was reduced by L-NAME, suggesting that neuronal, and not hemodynamic, mechanisms play a central role in this process.
A condition that resembles NMDA exposure in vivo is cerebral ischemia. Ischemia induces a surge in extracellular glutamate (Globus et aI., 1988 ) that activates the NMDA receptors, leading to excito toxic damage (Meldrum, 1989) . Furthermore, since neuronal NOS is a calcium/calmodulin-dependent enzyme, an enhanced production of NO may well occur following cerebral ischemia. Indeed, a recent study demonstrated an increase in the concentra tion of NO upon initiation of middle cerebral artery occlusion and following reperfusion (Malinski et aI., 1993) . Further support for the dual role of NO in vivo is evident from the diverse effects of NOS in hibitors on ischemic outcome. Some studies report a protective effect of NOS inhibitors against isch emic damage (Nowicki et aI., 1991; Buisson et ai. , 1992; Nagafuji et aI., 1992) . Conversely, others ob-serve either no effect (Dawson et aI., 1992) or aug mentation of ischemia-induced neuronal injury with NOS inhibitors (Yamamoto et aI., 1992 ) and a de crease in infarct size following administration of L-arginine (Morikawa et aI., 1992) , the precursor for NO synthesis. Similarly to our data with the NMDA injections, these results suggest that physiological mechanisms modulated by NO can operate both to enhance ischemic cell damage and to reduce it; the net effect of these multiple mechanisms likely de pends on the magnitude of involvement of the neu ronal versus hemodynamic influences of NO. This hypothesis is supported by a recent study demon strating that infarct size was smaller in mice defi cient in neuronal NOS compared to normal mice (Huang et aI., 1994) .
In summary, our results address a key question regarding the extent to which NO synthesis partic ipates in NMDA receptor-mediated toxicity in vivo. The data show that the involvement of NO depends on the NMDA dose and on the participation of he modynamic mechanisms secondary to NMDA ex posure. Further studies using specific NOS modu lators or making use of transgenic mice that lack neuronal NOS may enable us to dissect out the in volvement of the neuronal versus endothelial pool of NO in the excitotoxic process in vivo.
